Skip to the beginning of the images gallery

Technologies Transforming the Biomanufacturing Landscape

Translating Technology Innovation to Market Competitiveness

INDUSTRY
Healthcare

SECTOR
Life Sciences

RELEASE DATE
25-Jun-2019

REGION
Global

DELIVERABLE TYPE
Technology Research

RESEARCH CODE
D8BA-01-00-00-00

SKU
HC03189-GL-TR_23302

Technologies Transforming the Biomanufacturing Landscape
Published on: 25-Jun-2019 | SKU: HC03189-GL-TR_23302

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink

downloadable link $0.00

Select all

Qty

Request Sample

Need more details?

Description

Overall Impact of Biomanufacturing Technology Innovations
Impact on Unmet Needs
Pharmaceutical companies perceive analytical services as important. There is a need for a robust platform that enables the provision of such services. Pharma firms are outsourcing crucial processes and are utilizing services such as analytics, research, process development, bio-analytical testing, and regulatory support.

Impact on Capturing Investment Opportunities
As the biologics market is witnessing increased outsourcing of mammalian cell culture activities, a significant expansion of capacity is expected in this area. Biopharma companies will outsource cell line development to specialist vendors, including professional biological contract manufacturing organizations (BioCMOs), or license it from them.

Impact on Technology Implementation
Contract development and manufacturing organizations (CDMOs) need to focus on the attractive opportunity in disposables/ single use bioreactors, improvements in upstream & downstream technologies, advances in lyophilisation & increased application of PAT, continuous bio-manufacturing, new cell culture techniques, and modular facilities/pod manufacturing.

Impact on Strategic Collaborations
CDMOs need to broaden their services to grab emerging opportunities in outsourcing of biologic and biosimilar manufacturing driven by mid and small biotech names. Large BioCDMOs will continue to invest in drug development and clinical manufacturing capabilities through M&A activities.

Impact on Disruptive Business Models
Expanding services of CMOs into the early-stage development of drugs, emergence of virtual biotech, out-licensing, and risk sharing between pharma and CMOs is disrupting the traditional business models. By offering value-added services to pharma companies, CMOs need to redefine themselves as CDMOs and integrate themselves into the value chain of companies.

Table of Contents

1.0 Executive Summary

1.1 Research Focus: Biomanufacturing Technology Synergy

1.2 Research Scope: Foreseeing Challenges and Solutions

1.3 Analysis Framework: Frost & Sullivan’s Core Value

1.4 Research Methodology

2.0 Technology Landscape and Trends

2.1 Biomanufacturing Facts and Challenges

2.2 Biomanufacturing Complexity

2.3 Biomanufacturing Growth Opportunities

3.0 Technology Status Review and Assessment

3.1 Biopharmaceutical Manufacturing: Smart Industrial Operations

3.2 Biopharmaceutical Manufacturing: Process Intensification

3.3 Biopharmaceutical Manufacturing: Upstream

3.4 Biopharmaceutical Manufacturing: Downstream

3.5 Biopharmaceutical Manufacturing: Different Levels of Flexibility

3.6 Process Technology Disruptiveness Opportunities

3.7 Bioprocessing Units and Facility Types: Fed Batch

3.8 Large-scale Stainless Steel Fed Batch

3.9 Bioprocessing Units and Facility Types: Single Use Bioreactors

3.10 Single Use Bioreactors

3.11 Bioprocessing Units and Facility Types: Small-scale Bioreactors

3.12 Small Scale Bioreactors

4.0 Technology Radar Intelligent Solutions

4.1 Biomonitoring Technology Coming Next Decade

4.2 Evolving Process Control and Monitoring: Value Chain Excellence

4.3 Analysis of Key Biomonitoring Trends

4.4 Biomonitoring, Process Solutions Services and Bioprocessing

4.5 Evolving Process Control and Monitoring

4.6 Innovations in Biomonitoring Systems

4.7 Roadmap for Biomonitoring Systems

5.0 Market Potential and Technology Adoption

5.1 Biomonitoring Market Potential

5.2 Overall Environmental Impact Factors

5.3 Best-fit Industry Partnerships: SWOT Analysis

5.4 Novel Business Models in Biomanufacturing

5.5 Partners Business and Technology Capabilities

5.6 Market Adoption: Illustrative Case Using Single Use Technology

6.0 Business Landscape and Intellectual Property Analysis

6.1 Actionable Impact on Customers

6.2 Insights on Bioprocessing

6.3 Repercussions in Business and Processes

6.4 Technology Transfer Assessment

7.0 Technology Roadmapping

7.1 Typical Value Chain Interactive Model

7.2 Biomanufacturing Technology Roadmap

7.3 Industry Intersection Model

7.4 Crossmapping Continuous Monitoring Innovations

7.5 Key Remarks to Success in the Industry 4.0 Era

8.0 Performance Benchmarking and Strategic Recommendations

8.1 Biomonitoring Assessment and Prioritization Criteria

8.2 Transformation in Industry Eco-system

8.3 Companies Leading the Biomanufacturing Space

8.4 Biomanufacturing Competitive Environment

8.5 Major Stakeholders: Lonza

8.6 Lonza Value Proposition

8.7 Major Stakeholders: Boehringer Ingelheim (BioXcellence)

8.8 Boehringer Ingelheim Value Proposition

8.9 Major Stakeholders: Catalent

8.10 Catalent Value Proposition

8.11 Major Stakeholders: Patheon (Thermo Fisher Scientific)

8.12 Patheon Value Proposition

8.13 Major Stakeholders: Samsung BioLogics

8.14 Samsung BioLogics Value Proposition

8.15 Major Stakeholders: Wuxi Biologics

8.16 Wuxi Biologics Value Proposition

8.17 Major Stakeholders: AGC Biologics

8.18 AGC Biologics Value Proposition

8.19 The Final Chart: Innovation Index Radar

8.20 Strategic Imperatives for Future Growth

9.0 Key Industry Contacts

9.1 Key Industry Influencers

9.2 Key Industry Experts

9.3 Key Industry Authorities

9.4 Key Industry Advisors

9.5 Key Industry Mentors

Legal Disclaimer

Request Sample

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Life Sciences research

13 Jan 2025 | Global | Market Outlook

Top 6 Growth Opportunities for the Digital Health Industry, 2025

Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...

Cybersecurity in Healthcare, United States, 2024

Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...

Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...

Frost Radar™: Enterprise Conversational AI in Healthcare, 2024

This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...

Generative AI in Payer and Provider IT Transformation, Global, 2024-2029

The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...

Report download
Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:

Strategic Imperatives
Growth Opportunities
Best Practices
Companies to Action

Impacting your company's future growth potential.

Details

Overall Impact of Biomanufacturing Technology Innovations Impact on Unmet Needs Pharmaceutical companies perceive analytical services as important. There is a need for a robust platform that enables the provision of such services. Pharma firms are outsourcing crucial processes and are utilizing services such as analytics, research, process development, bio-analytical testing, and regulatory support. Impact on Capturing Investment Opportunities As the biologics market is witnessing increased outsourcing of mammalian cell culture activities, a significant expansion of capacity is expected in this area. Biopharma companies will outsource cell line development to specialist vendors, including professional biological contract manufacturing organizations (BioCMOs), or license it from them. Impact on Technology Implementation Contract development and manufacturing organizations (CDMOs) need to focus on the attractive opportunity in disposables/ single use bioreactors, improvements in upstream & downstream technologies, advances in lyophilisation & increased application of PAT, continuous bio-manufacturing, new cell culture techniques, and modular facilities/pod manufacturing. Impact on Strategic Collaborations CDMOs need to broaden their services to grab emerging opportunities in outsourcing of biologic and biosimilar manufacturing driven by mid and small biotech names. Large BioCDMOs will continue to invest in drug development and clinical manufacturing capabilities through M&A activities. Impact on Disruptive Business Models Expanding services of CMOs into the early-stage development of drugs, emergence of virtual biotech, out-licensing, and risk sharing between pharma and CMOs is disrupting the traditional business models. By offering value-added services to pharma companies, CMOs need to redefine themselves as CDMOs and integrate themselves into the value chain of companies.

More Information

More Information
Deliverable Type	Technology Research
No Index	No
Podcast	No
Author	Cecilia Van Cauwenberghe
Industries	Healthcare
WIP Number	D8BA-01-00-00-00
Is Prebook	No